At the news
? NEUTRALIMPACT 4/10 6-K filed Jul 28, 2026 at 13:10 ET
GSK announced plans to build a new flagship R&D centre on the Cambridge Biomedical Campus in the UK, with a £400 million investment over three years. The 300,000 sq ft site will consolidate UK R&D operations, housing over 1,000 scientists focused on Oncology, Respiratory, Hepatology, Vaccines, and HIV, while vacating the Stevenage site by 2029. This is a long-term infrastructure commitment with no immediate financial impact on earnings or guidance, and the stock impact is likely neutral in the near term.
- GSK plans a £400 million investment over 3 years to establish a new R&D centre on the Cambridge Biomedical Campus in the UK.
- The new 300,000 square foot site will house over 1,000 GSK scientists and consolidate UK R&D operations.
- GSK will vacate its existing R&D site at Stevenage, with a phased employee move by 2029.
- The company will also upgrade its R&D laboratories at Ware, Hertfordshire, as part of the plan.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access